XOMA Royalty【XOMAO】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

25.73

買値

25.12

売値

26.13

出来高

1,378

25.51 日の範囲 25.73

0.00 52 週間の範囲 0.00

時価総額

303.111M

前日終値

25.51

始値

25.55

時刻

25.64

最終取引時間

財務取引量

US$ 35,182

VWAP

25.53

平均取引量 (3 か月)

発行済株式数

11,782,723

配当利回り

10.17%

PER

-7.75

1 株当たり利益 (EPS)

-3.47

歳入

4.76M

純利益

-40.83M

XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolo... XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.xoma.com

本社

Wilmington, Delaware, USA

設立

XOMA Royalty Corporation is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker XOMAO. The last closing price for XOMA Royalty was US$25.51. Over the last year, XOMA Royalty shares have traded in a share price range of US$ 0.00 to US$ 0.00.

XOMA Royalty currently has 11,782,723 shares in issue. The market capitalisation of XOMA Royalty is US$300.54 million. XOMA Royalty has a price to earnings ratio (PE ratio) of -7.75.

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of...

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and...

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience’s...

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now holds over 100 assets ranging from revenue-generating...

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

MIPLYFFA™ is the first therapy approved for use in patients with NPC, a rare genetic disorder XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	PR
4	0	0	0	0	0	0	0	PR
12	0	0	0	0	0	0	0	PR
26	0	0	0	0	0	0	0	PR
52	0	0	0	0	0	0	0	PR
156	0	0	0	0	0	0	0	PR
260	0	0	0	0	0	0	0	PR

XOMAO - Frequently Asked Questions (FAQ)

What is the current XOMA Royalty share price?

The current share price of XOMA Royalty is US$ 25.73

How many XOMA Royalty shares are in issue?

XOMA Royalty has 11,782,723 shares in issue

What is the market cap of XOMA Royalty?

The market capitalisation of XOMA Royalty is USD 300.54M

What is the 1 year trading range for XOMA Royalty share price?

XOMA Royalty has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of XOMA Royalty?

The price to earnings ratio of XOMA Royalty is -7.75

What is the cash to sales ratio of XOMA Royalty?

The cash to sales ratio of XOMA Royalty is 66.49

What is the reporting currency for XOMA Royalty?

XOMA Royalty reports financial results in USD

What is the latest annual turnover for XOMA Royalty?

The latest annual turnover of XOMA Royalty is USD 4.76M

What is the latest annual profit for XOMA Royalty?

The latest annual profit of XOMA Royalty is USD -40.83M

What is the registered address of XOMA Royalty?

The registered address for XOMA Royalty is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801

What is the XOMA Royalty website address?

The website address for XOMA Royalty is www.xoma.com

Which industry sector does XOMA Royalty operate in?

XOMA Royalty operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
MYSZMy Size Inc	US$ 4.2001 (211.12%)	121.03M
NVNINVNI Group Ltd	US$ 8.26 (209.36%)	78.06M
TPICTPI Composites Inc	US$ 2.45 (100.82%)	34M
ICGIntchains Group Ltd	US$ 8.77 (88.60%)	527.94k
HSDTHelius Medical Technologies Inc	US$ 0.884851 (84.34%)	121.95M
CYNCYNGN Inc	US$ 0.4603 (-71.41%)	27.5M
MTEMMolecular Templates Inc	US$ 0.1502 (-57.09%)	8.63M
PRFXPainReform Ltd	US$ 5.15 (-53.85%)	2.84M
GALTGalectin Therapeutics Inc	US$ 1.03 (-48.50%)	8.58M
BCABBioAtla Inc	US$ 0.6923 (-41.82%)	5.96M
EDBLEdible Garden AG Inc	US$ 0.24 (65.06%)	354.33M
NVDANVIDIA Corporation	US$ 134.70 (3.08%)	310.19M
APTOAptose Biosciences Inc	US$ 0.28 (64.51%)	306.25M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.606999 (6.49%)	293.22M
PLTRPalantir Technologies Inc	US$ 80.55 (8.54%)	281.23M